Illumina Gets Medicare Boost for Cancer Test, Shares Climb

Illumina Inc. (NASDAQ:ILMN) shares are up on Tuesday following news that the company has secured reimbursement for its FDA-approved TruSight Oncology Comprehensive test.

CMS Reimbursement to Boost ILMN Adoption

The reimbursement from the Centers for Medicare and Medicaid Services (CMS) will allow the TruSight Oncology Comprehensive test to be reimbursed at a rate of $2,989.55 per test, effective January 1.

The decision is expected to enhance the adoption of comprehensive genomic profiling in the U.S. healthcare system, enabling more laboratories to deliver clinically actionable results.

The test assesses over 500 genes to inform treatment decisions, promoting broader access to precision oncology diagnostics across various healthcare settings. The move is anticipated to drive growth, as approximately 60% of Illumina’s sequencing consumables revenue was attributed to clinical customers last year.

ILMN Shows Positive Trend Above Moving Average

Illumina’s stock is currently trading 2.65% above its 12-month moving average, reflecting a positive trend over the past year. Shares have increased 2.9% over the past 12 months and are currently positioned closer to their 52-week highs than lows.

The RSI is currently neutral, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, suggesting bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $151.50
Key Support: $130.50

ILMN Earnings Forecast and Analyst Ratings

Investors are looking ahead to the next earnings report on February 5, 2026.

EPS Estimate: $1.22 (Up from $0.95 YoY)
Revenue Estimate: $1.10 billion (Down from $1.10 billion YoY)
Valuation: P/E of 31.8x (Indicates premium valuation)

Analyst Consensus & Recent Actions:

The stock carries a Neutral Rating with an average price target of $130.24. Recent analyst moves include:

TD Cowen: Hold (Raised Target to $140.00) (January 7)
Guggenheim: Buy (Raised Target to $144.00) (January 5)
Canaccord Genuity: Hold (Raised Target to $130.00) (December 22, 2025)

Valuation Insight: While the stock trades at a premium P/E multiple, the consensus and 28% expected earnings growth suggest analysts view this growth as justification for the current valuation.

ILMN Scores High on Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Illumina, highlighting its strengths and weaknesses compared to the broader market:

Momentum: Bullish (Score: 86.32/100) — Stock is outperforming the broader market.
Quality: Weak (Score: 4.59/100) — Balance sheet may raise concerns.
Value: Risk (Score: 18.92/100) — Trading at a steep premium relative to peers.
Growth: Strong (Score: 82.49/100) — Indicates potential for future expansion.

The Verdict: Illumina’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum score indicates strong short-term performance, the low Value score warns that the stock is priced for perfection—investors should proceed with caution.